The 36-month beta value for VRTX is at 0.40. Analysts have varying views on the stock, with 12 analysts rating it as a “buy,” 10 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for VRTX is 257.44M, and currently, shorts hold a 1.58% of that float. The average trading volume for VRTX on October 18, 2024 was 1.10M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VRTX) stock’s latest price update
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX)’s stock price has increased by 2.36 compared to its previous closing price of 487.25. However, the company has seen a 4.74% increase in its stock price over the last five trading sessions. zacks.com reported 2024-10-14 that Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $484.94, moving +0.67% from the previous trading session.
VRTX’s Market Performance
Vertex Pharmaceuticals, Inc. (VRTX) has seen a 4.74% rise in stock performance for the week, with a 5.18% gain in the past month and a 1.46% surge in the past quarter. The volatility ratio for the week is 1.72%, and the volatility levels for the past 30 days are at 1.81% for VRTX. The simple moving average for the past 20 days is 6.45% for VRTX’s stock, with a 11.33% simple moving average for the past 200 days.
Analysts’ Opinion of VRTX
Barclays gave a rating of “Equal Weight” to VRTX, setting the target price at $509 in the report published on August 05th of the current year.
VRTX Trading at 5.15% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.33% of loss for the given period.
Volatility was left at 1.81%, however, over the last 30 days, the volatility rate increased by 1.72%, as shares surge +4.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.05% upper at present.
During the last 5 trading sessions, VRTX rose by +4.74%, which changed the moving average for the period of 200-days by +21.37% in comparison to the 20-day moving average, which settled at $468.50. In addition, Vertex Pharmaceuticals, Inc. saw 22.57% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from Biller Jonathan, who sale 999 shares at the price of $461.66 back on Oct 02 ’24. After this action, Biller Jonathan now owns 16,651 shares of Vertex Pharmaceuticals, Inc., valued at $461,198 using the latest closing price.
Biller Jonathan, the Officer of Vertex Pharmaceuticals, Inc., proposed sale 999 shares at $461.66 during a trade that took place back on Oct 02 ’24, which means that Biller Jonathan is holding shares at $461,198 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- -0.04 for the present operating margin
- 0.86 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc. stands at -0.05. The total capital return value is set at -0.02. Equity return is now at value -3.24, with -2.42 for asset returns.
Based on Vertex Pharmaceuticals, Inc. (VRTX), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -1.01. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -9.38.
Currently, EBITDA for the company is 3.93 billion with net debt to EBITDA at 175.32. When we switch over and look at the enterprise to sales, we see a ratio of 12.12. The receivables turnover for the company is 6.23for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.52.
Conclusion
In conclusion, Vertex Pharmaceuticals, Inc. (VRTX) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
